Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Myeloid, Chronic-Phase 2Bronchiolitis Obliterans Syndrome 2Recurrence 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Advanced Solid Tumors 1

Interventions

Brentuximab Vedotin 17fludarabine 9Cyclophosphamide 9dacetuzumab 6Lenalidomide 6Bortezomib 6ruxolitinib 5fludarabine phosphate 5Rituximab 5Melphalan 5Dexamethasone 4Busulfan 4lintuzumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Calcium Dobesilate 3Azacitidine 3vosaroxin 2spartalizumab 2ponatinib 2nilotinib 2Vincristine 2Thiotepa 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Rifampin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hematologic Diseases × asciminib × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡